Sera Prognostics Announces Major Publication Acceptance of PRIME Study Findings

Sera Prognostics Announces Publication Acceptance for PRIME Study

Sera Prognostics, Inc., known as The Pregnancy Company®, has made a landmark announcement regarding its ongoing efforts to enhance maternal and neonatal health. The company has revealed that the findings from its ambitious Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study have been accepted for publication in a peer-reviewed medical journal.

A Groundbreaking Study

The PRIME study is one of the most extensive research projects focused on preterm birth, a significant issue affecting maternal and neonatal health worldwide. Earlier this year, during the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, the abstract data from the study was featured as a late-breaking abstract, underscoring the importance and relevance of its findings in the medical community.

Zhenya Lindgardt, the President and CEO of Sera Prognostics, expressed enthusiasm about sharing the manuscript data with a broader audience, which will occur at upcoming medical meetings and events. This forthcoming publication is anticipated to stimulate conversations and enhance understanding concerning the risks associated with preterm births and the clinical interventions that could improve outcomes for mothers and their babies.

About Sera Prognostics

Sera Prognostics has established itself as a pivotal player in the health diagnostics domain, particularly dedicated to advancing the field of pregnancy care. With its headquarters situated in Salt Lake City, Utah, the company focuses on providing innovative pregnancy biomarker information, aiming to empower both healthcare providers and expectant mothers.

The company’s flagship product, the PreTRM® Test, is notable for being the only broadly validated blood-based biomarker test available commercially for early and individualized risk prediction of spontaneous preterm birth. This test is designed to analyze specific proteins present in the blood that are highly indicative of the likelihood of preterm birth.

How PreTRM® Test Works

The PreTRM® Test comes into play between weeks 18 and 20 of gestation, enabling healthcare professionals to identify women who may be at an increased risk for preterm births and associated complications. By providing this early detection, healthcare providers can make more informed and personalized clinical decisions tailored to each woman's specific risk profile, significantly enhancing the quality of care.

A Pioneering Commitment

Sera Prognostics remains committed to tackling the challenges associated with preterm birth, a condition that affects around 10% of infants born globally. The acceptance of the PRIME study findings for publication marks a significant step towards fostering greater awareness and understanding of preterm birth risks. It emphasizes the critical need for continued research and innovation within the medical community to improve healthcare outcomes for mothers and infants alike.

In summary, with the acceptance of the PRIME study for publication, Sera Prognostics is not only advancing the dialogue around maternal and neonatal health, but also reinforcing its role as a leader in preventative care and precision medicine.

The company continues to look forward to further sharing insights and findings from the PRIME study, as well as introducing new advancements in their approach to pregnancy care. This aligns with their overarching goal of improving the lives of women and babies through precision health solutions.

Conclusion

The landscape of maternal and neonatal healthcare is evolving, and with studies like PRIMEs paving the way, there’s a profound potential to shift paradigms regarding preterm birth management. Sera Prognostics is at the forefront of this evolution, making significant contributions toward enhancing health outcomes for mothers and newborns through innovative technologies and research findings. Stay tuned for more updates as their findings are published and discussed in medical forums worldwide.